Vanguard Global Advisers
NTLA icon

Vanguard Global Advisers’s Intellia Therapeutics NTLA Stock Holding History

Vanguard Global Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$939K Buy
55,491
+8,795
+19% +$123K ﹤0.01% 1785
2026
Q1 		$599K Buy
+46,696
New +$595K ﹤0.01% 1955

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Vanguard Global Advisers's NTLA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Intellia Therapeutics (NTLA) stake by 19% in Q2 2026, buying an estimated $123K and bringing the position to 55,491 shares worth $939K. The position accounts for ﹤0.01% of the portfolio, ranked #1785.

Vanguard Global Advisers first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 325 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Vanguard Global Advisers held 55,491 shares of Intellia Therapeutics worth $939K as of Q2 2026.
  • Vanguard Global Advisers bought 8,795 Intellia Therapeutics shares in Q2 2026, an estimated $123K.
  • Intellia Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1785 holding.
  • Vanguard Global Advisers first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 325 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.